Karyopharm Therapeutics (NASDAQ:KPTI) was upgraded by Zacks Investment Research from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Tuesday, Zacks.com reports. The firm presently has a $21.00 target price on the stock. Zacks Investment Research‘s target price would suggest a potential upside of 13.45% from the stock’s current price.
According to Zacks, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. “
Several other equities research analysts have also issued reports on KPTI. Canaccord Genuity reaffirmed a “buy” rating and set a $22.00 price target on shares of Karyopharm Therapeutics in a research note on Thursday, December 12th. Bank of America upgraded Karyopharm Therapeutics from an “underperform” rating to a “neutral” rating in a research report on Friday, January 3rd. BidaskClub raised Karyopharm Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Friday, December 20th. Robert W. Baird set a $25.00 target price on Karyopharm Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, September 24th. Finally, Wedbush boosted their target price on Karyopharm Therapeutics from $15.00 to $18.00 in a research report on Wednesday, November 6th. Two analysts have rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the stock. Karyopharm Therapeutics presently has an average rating of “Buy” and an average target price of $22.14.
Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Monday, November 4th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.17. Karyopharm Therapeutics had a negative net margin of 909.24% and a negative return on equity of 187.25%. The company had revenue of $13.15 million during the quarter, compared to analyst estimates of $1.61 million. On average, sell-side analysts predict that Karyopharm Therapeutics will post -3.13 earnings per share for the current year.
In related news, insider Sharon Shacham sold 10,000 shares of the stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $12.00, for a total transaction of $120,000.00. Following the completion of the sale, the insider now directly owns 741,134 shares in the company, valued at approximately $8,893,608. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Michael Kauffman sold 20,000 shares of the stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $14.17, for a total value of $283,400.00. Insiders sold 135,463 shares of company stock valued at $2,182,510 over the last three months. 13.26% of the stock is currently owned by insiders.
Hedge funds have recently modified their holdings of the stock. Tower Research Capital LLC TRC boosted its holdings in Karyopharm Therapeutics by 536.6% during the 3rd quarter. Tower Research Capital LLC TRC now owns 3,476 shares of the company’s stock valued at $34,000 after acquiring an additional 2,930 shares during the period. Bank of Montreal Can purchased a new stake in Karyopharm Therapeutics during the 2nd quarter valued at about $29,000. Virtu Financial LLC purchased a new stake in Karyopharm Therapeutics during the 3rd quarter valued at about $99,000. Envestnet Asset Management Inc. boosted its holdings in Karyopharm Therapeutics by 12.4% during the 2nd quarter. Envestnet Asset Management Inc. now owns 11,980 shares of the company’s stock valued at $72,000 after acquiring an additional 1,319 shares during the period. Finally, Commonwealth Equity Services LLC purchased a new stake in Karyopharm Therapeutics during the 3rd quarter valued at about $124,000. Institutional investors own 93.14% of the company’s stock.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for
the treatment of cancer and other major diseases. Karyopharm’s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).
Recommended Story: Why do analysts give a neutral rating?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.